352 Shares in Edwards Lifesciences Co. (NYSE:EW) Acquired by Crowley Wealth Management Inc.

Crowley Wealth Management Inc. purchased a new position in shares of Edwards Lifesciences Co. (NYSE:EW) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 352 shares of the medical research company’s stock, valued at approximately $26,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in Edwards Lifesciences by 10.4% during the 4th quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company’s stock worth $5,117,845,000 after buying an additional 6,537,494 shares during the last quarter. LPL Financial LLC grew its stake in Edwards Lifesciences by 8.8% during the 4th quarter. LPL Financial LLC now owns 261,680 shares of the medical research company’s stock worth $19,372,000 after buying an additional 21,219 shares during the last quarter. Simplify Asset Management Inc. purchased a new position in shares of Edwards Lifesciences in the 4th quarter valued at approximately $5,979,000. KLP Kapitalforvaltning AS purchased a new position in shares of Edwards Lifesciences in the 4th quarter valued at approximately $16,436,000. Finally, Sei Investments Co. grew its stake in shares of Edwards Lifesciences by 45.4% in the 4th quarter. Sei Investments Co. now owns 348,444 shares of the medical research company’s stock valued at $25,795,000 after purchasing an additional 108,821 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

EW has been the topic of several analyst reports. Stifel Nicolaus upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and lifted their target price for the company from $75.00 to $90.00 in a research note on Thursday, January 30th. Morgan Stanley lifted their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 12th. Truist Financial reiterated a “hold” rating and issued a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Piper Sandler lifted their target price on Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research note on Wednesday, February 12th. Finally, Evercore ISI lowered their target price on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a research note on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Hold” and a consensus target price of $79.95.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 9,500 shares of the business’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $67.96, for a total value of $645,620.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,189,770.56. The trade was a 16.83 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Scott B. Ullem sold 11,250 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $75.76, for a total value of $852,300.00. Following the completion of the transaction, the chief financial officer now owns 30,561 shares of the company’s stock, valued at $2,315,301.36. The trade was a 26.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 51,303 shares of company stock valued at $3,715,776 over the last three months. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $70.46 on Monday. The stock has a fifty day moving average price of $71.42 and a 200 day moving average price of $70.38. The stock has a market cap of $41.42 billion, a PE ratio of 10.11, a P/E/G ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Sell-side analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.